Use MDR first when the product has a medical purpose, is an accessory to a medical device, or falls into an non-medical product group once common specifications apply.
is not always displaced by MDR. For products subject to specific EU safety requirements, GPSR applies to aspects and risks that those requirements do not cover; its duties also apply to outside MDR scope.
Start with MDR qualification, but do not treat MDR and as an automatic either-or choice. MDR governs medical devices, accessories, and covered products. GPSR governs and remains relevant to aspects and risks not covered by product-specific EU safety requirements. The result can be MDR only, GPSR only, or MDR plus residual GPSR duties for an uncovered consumer-safety risk. For products subject to Union harmonisation legislation such as the MDR, GPSR Article 2(1) excludes Chapter IIa, Chapter III, Section 1, Chapters V and VII, and Chapters IX to XI. Do not apply the GPSR economic-operator duties in that excluded section, including Article 9 technical documentation, to an MDR device merely because a residual risk is identified. Article 20 accident notification is in Chapter III, Section 2 and is not covered by that section exclusion. Assess its applicability separately under Article 2, including whether product-specific EU safety requirements cover the relevant aspect or risk.
Side-by-side comparison
MDR vs GPSR: product and risk boundary
A cited-source comparison for deciding whether a product belongs under MDR, , or both because GPSR covers an aspect or risk not addressed by the applicable product-specific safety rules.
Use MDR for medical devices, accessories, intended-purpose classification, conformity assessment, technical documentation, clinical evidence, PMS, vigilance, UDI, and EUDAMED.
Second framework
GPSR / general product safety
Use for outside MDR and for aspects or risk categories not covered by applicable product-specific EU safety requirements. Confirm the actor and duty under GPSR rather than treating it as a generic safety label.
MDR analysis starts with intended purpose, medical claims, software outputs, IFU statements, accessory use, and user population.
covers items intended for consumers and items not intended for consumers that are likely, under reasonably foreseeable conditions, to be used by consumers. Its safety assessment considers the product, presentation, consumer categories, effect on other products, and evolving or learning functions where relevant.
Preserve claim evidence with the scope decision because a marketing or IFU change can change the regulatory route.
Sets the consumer-product safety trigger used as the GPSR-side fallback.
Where products are subject to specific safety requirements imposed by Union law, this Regulation applies only to those aspects and risks or categories of risks which are not covered by those requirements.
MDR evidence should include qualification rationale, classification rule, technical documentation, clinical evaluation, PMS or PMCF where relevant, vigilance procedures, UDI data, and EUDAMED records.
For outside Union harmonisation legislation, evidence should include internal risk analysis, technical documentation, traceability, contact details, instructions and safety information, and recall or accident-response records. Apply Article 2(1) chapter exclusions to MDR products.
Use a shared evidence index only if each record is tagged to the regime and claim it actually supports.
MDR devices need PMS and vigilance routing, including serious-incident and field safety corrective action assessment.
Where Article 20 applies after the Article 2 scope assessment, manufacturers must ensure that accidents caused by a product are notified through the Safety Business Gateway without undue delay after learning of them. Article 20 covers deaths and serious adverse effects on health and safety; it is in Chapter III, Section 2 and is not categorically excluded for products subject to Union harmonisation legislation. Assess the relevant product-specific safety requirements before applying it to an MDR device. Dangerous-product corrective-action and recall communications follow separate GPSR conditions.
Incident intake should ask whether the product is an MDR device, an product, a dual-purpose product, or outside the MDR file.
Current consolidated Article 2 includes the Chapter IIa exclusion. Article 20 is in Chapter III, Section 2; its application requires the Article 2 product and risk scope assessment.
If a medical purpose, accessory relationship, classification rule, category, or MDR PMS/vigilance trigger is present, keep the issue in the MDR workstream.
has applied since 13 December 2024. For products subject to its Article 9 manufacturer duties, technical documentation must be retained for 10 years after the product is placed on the market; notification timing depends on whether the event is an accident, a dangerous product, or a recall.
Record the product facts, MDR and conclusions, the scope or residual-risk basis, the responsible actor, the applicable notification route, and the next review trigger.
MDR and can overlap on a product's non-medical risks, but MDR remains the first check when the intended purpose is medical or the product is an accessory or product.
handles the safety gaps that remain after sector-specific legislation has been checked, including products that are outside MDR scope.
Map shared controls to the MDR requirement and the residual aspect or risk they support; do not treat the two legal conclusions as interchangeable.
Grounds only the cautious safety-net concept for products not covered by sector-specific legislation.
not covered by sector-specific EU harmonisation legislation
Qualification and safety-assessment inputs
MDR
MDR analysis starts with intended purpose, medical claims, software outputs, IFU statements, accessory use, and user population.
GPSR / general product safety
covers items intended for consumers and items not intended for consumers that are likely, under reasonably foreseeable conditions, to be used by consumers. Its safety assessment considers the product, presentation, consumer categories, effect on other products, and evolving or learning functions where relevant.
Operational implication
Preserve claim evidence with the scope decision because a marketing or IFU change can change the regulatory route.
Sets the consumer-product safety trigger used as the GPSR-side fallback.
Where products are subject to specific safety requirements imposed by Union law, this Regulation applies only to those aspects and risks or categories of risks which are not covered by those requirements.
Conformity and safety evidence
MDR
MDR evidence should include qualification rationale, classification rule, technical documentation, clinical evaluation, PMS or PMCF where relevant, vigilance procedures, UDI data, and EUDAMED records.
GPSR / general product safety
For outside Union harmonisation legislation, evidence should include internal risk analysis, technical documentation, traceability, contact details, instructions and safety information, and recall or accident-response records. Apply Article 2(1) chapter exclusions to MDR products.
Operational implication
Use a shared evidence index only if each record is tagged to the regime and claim it actually supports.
Supports GPSR-side core obligations for consumer products.
manufacturers shall carry out an internal risk analysis and draw up technical documentation
Post-market and incident routing
MDR
MDR devices need PMS and vigilance routing, including serious-incident and field safety corrective action assessment.
GPSR / general product safety
Where Article 20 applies after the Article 2 scope assessment, manufacturers must ensure that accidents caused by a product are notified through the Safety Business Gateway without undue delay after learning of them. Article 20 covers deaths and serious adverse effects on health and safety; it is in Chapter III, Section 2 and is not categorically excluded for products subject to Union harmonisation legislation. Assess the relevant product-specific safety requirements before applying it to an MDR device. Dangerous-product corrective-action and recall communications follow separate GPSR conditions.
Operational implication
Incident intake should ask whether the product is an MDR device, an product, a dual-purpose product, or outside the MDR file.
Current consolidated Article 2 includes the Chapter IIa exclusion. Article 20 is in Chapter III, Section 2; its application requires the Article 2 product and risk scope assessment.
MDR routing and GPSR deadlines
MDR
If a medical purpose, accessory relationship, classification rule, category, or MDR PMS/vigilance trigger is present, keep the issue in the MDR workstream.
GPSR / general product safety
has applied since 13 December 2024. For products subject to its Article 9 manufacturer duties, technical documentation must be retained for 10 years after the product is placed on the market; notification timing depends on whether the event is an accident, a dangerous product, or a recall.
Operational implication
Record the product facts, MDR and conclusions, the scope or residual-risk basis, the responsible actor, the applicable notification route, and the next review trigger.
Articles 23-35 establish Safety Gate and market-surveillance cooperation for dangerous products.
Overlap and reuse
MDR
MDR and can overlap on a product's non-medical risks, but MDR remains the first check when the intended purpose is medical or the product is an accessory or product.
GPSR / general product safety
handles the safety gaps that remain after sector-specific legislation has been checked, including products that are outside MDR scope.
Operational implication
Map shared controls to the MDR requirement and the residual aspect or risk they support; do not treat the two legal conclusions as interchangeable.
Grounds only the cautious safety-net concept for products not covered by sector-specific legislation.
not covered by sector-specific EU harmonisation legislation
Practical decision rule
Practical decision rule
Use MDR when the facts match the left-side scope, trigger, and evidence rows.
Use when the product is in its consumer-product scope or when its residual-risk rule applies to an uncovered aspect or risk.
Reuse controls only where the comparison rows show the same actor, obligation, timing, and evidence basis.
1
Section 1
Start with intended purpose and claims
MDR classification and qualification turn on the product's intended purpose. The MDR text requires classification rules to be applied by intended purpose, and technical documentation must identify the device, intended purpose, risk class, and applicable rule. That makes marketing claims, instructions for use, software outputs, clinical claims, and accessories the first boundary checks.
If the product is sold as a wellness, beauty, sports, comfort, or general consumer product, do not assume that the absence of a medical claim ends the analysis. brings listed groups of products without an intended medical purpose into the MDR framework once common specifications apply.
scope also has exclusions. Medicinal products, food and feed, living plants and animals, certain transport equipment, and products clearly marked for repair or reconditioning before use are among the categories handled outside or specially under Article 2. A professional product is not automatically excluded if consumers are reasonably likely to use it.
Collect public claims, packaging, IFU text, app screens, sales scripts, website copy, and distributor listings before deciding MDR scope.
Check whether the product is a medical device, an accessory, a product listed in MDR , or a non-medical consumer product requiring a separate general product-safety review.
Record the facts that drove the answer; a later claim change can move the product from a general product-safety review into MDR or work.
Supports the point that listed products without an intended medical purpose can fall into the MDR framework through Annex XVI common specifications.
products without an intended medical purpose listed in Annex XVI
Recommended next step
Turn the boundary check into a cited scope record
Use the MDR sources, Annex XVI checks, claim review, and post-market routing rule to separate medical-device obligations from general product-safety follow-up.
Use Annex XVI before treating a non-medical product as ordinary GPSR work
is the main trap in an MDR-versus-general-product-safety comparison. A product can lack a medical purpose and still be pulled into MDR-style controls if it belongs to an Annex XVI group covered by common specifications.
MDCG 2023-6 also warns against casually borrowing clinical data from analogous medical devices for non-medical products. The working sequence is: qualify the product, check Annex XVI, identify any MDR safety requirements that apply, and then assess whether covers the product or a remaining risk.
Check whether the product is a contact lens or eye-contact product, dermal or mucous membrane filler, body-modification implant, equipment used to reduce or remove adipose tissue, skin-treatment equipment, or brain-stimulation equipment in the family.
For dual-purpose products, split the medical and non-medical intended purposes and map evidence to the purpose it actually supports.
If applies, build MDR evidence instead of relying on a generic consumer-product safety file.
Supports the caution that equivalence between a non-medical Annex XVI product and an analogous medical device is generally not straightforward.
a comparison is not possible between a medical device and a product without an intended medical purpose
3
Section 3
Keep MDR vigilance separate from general product-safety alerting
For devices in MDR scope, post-market surveillance and vigilance are part of the MDR file. The MDR requires procedures for PMS and vigilance, and the Blue Guide describes medical devices as having a specific vigilance system for serious incidents.
For in scope, manufacturers must ensure the general safety requirement is met, perform an internal risk analysis, prepare and update technical documentation, maintain product identification and traceability information, and keep the technical documentation available to market-surveillance authorities for 10 years after placement on the market. GPSR also uses the Safety Business Gateway for accident and dangerous-product notifications. These duties do not replace MDR PMS and vigilance for a device.
For MDR devices, keep PMS plans, PMCF logic where relevant, complaint handling, serious-incident assessment, field safety corrective action records, and EUDAMED or national-process evidence together.
For non-MDR , open a separate general product-safety assessment instead of filing the issue only in the MDR technical documentation.
For mixed portfolios, maintain a routing rule that sends medical-device incidents to MDR vigilance review and non-device consumer-product hazards to a product-safety review.
Articles 2 and 9 support residual GPSR coverage, the general safety requirement, manufacturer risk analysis, technical documentation, traceability, and the 10-year retention period; Articles 9(8), 10(2)(c), 11(8), 12(4), 20, 22, and 27 govern dangerous-product and accident notifications through the Safety Business Gateway.
Supports the consumer-product safety side of the comparison.
Sets the consumer-product safety trigger used as the GPSR-side fallback.
Supports GPSR-side core obligations for consumer products.
Show 3 more
Supports GPSR-side accident and recall routing.
Articles 23-35 establish Safety Gate and market-surveillance cooperation for dangerous products.
Grounds the GPSR fallback for risks not covered by sector-specific legislation.
"This Regulation lays down essential rules on the safety of consumer products placed or made available on the market."
More quoted passages
"Where products are subject to specific safety requirements imposed by Union law, this Regulation applies only to those aspects and risks or categories of risks which are not covered by those requirements."
"manufacturers shall carry out an internal risk analysis and draw up technical documentation"
"through the Safety Business Gateway"
"this Regulation applies only to those aspects and risks or categories of risks which are not covered by those requirements"
Binding GPSR source for scope, residual application to uncovered risks, economic-operator duties, technical documentation, traceability, Safety Business Gateway notifications, and recalls.
Articles 2 and 9 support residual GPSR coverage, the general safety requirement, manufacturer risk analysis, technical documentation, traceability, and the 10-year retention period; Articles 9(8), 10(2)(c), 11(8), 12(4), 20, 22, and 27 govern dangerous-product and accident notifications through the Safety Business Gateway.
Articles 9, 20, 22, and 52 support the retention, notification, and application-date distinctions.
Current consolidated Article 2 includes the Chapter IIa exclusion. Article 20 is in Chapter III, Section 2; its application requires the Article 2 product and risk scope assessment.